Modification  ||| S:0 E:13 ||| NNP
and  ||| S:13 E:17 ||| CC
implementation  ||| S:17 E:32 ||| NN
of  ||| S:32 E:35 ||| IN
NCCN  ||| S:35 E:40 ||| NNP
guidelines  ||| S:40 E:51 ||| NNS
on  ||| S:51 E:54 ||| IN
lymphomas  ||| S:54 E:64 ||| NN
in  ||| S:64 E:67 ||| IN
the  ||| S:67 E:71 ||| DT
Middle  ||| S:71 E:78 ||| NNP
East  ||| S:78 E:83 ||| NNP
and  ||| S:83 E:87 ||| CC
North  ||| S:87 E:93 ||| NNP
Africa  ||| S:93 E:100 ||| NNP
region  ||| S:100 E:107 ||| NN
In  ||| S:107 E:110 ||| IN
the  ||| S:110 E:114 ||| DT
Middle  ||| S:114 E:121 ||| NNP
East  ||| S:121 E:126 ||| NNP
and  ||| S:126 E:130 ||| CC
North  ||| S:130 E:136 ||| NNP
Africa  ||| S:136 E:143 ||| NNP
( ||| S:143 E:144 ||| -LRB-
MENA ||| S:144 E:148 ||| NNP
)  ||| S:148 E:150 ||| -RRB-
region ||| S:150 E:156 ||| NN
,  ||| S:156 E:158 ||| ,
cancer  ||| S:158 E:165 ||| NN
has  ||| S:165 E:169 ||| VBZ
many  ||| S:169 E:174 ||| JJ
epidemiologic  ||| S:174 E:188 ||| NN
and  ||| S:188 E:192 ||| CC
clinical  ||| S:192 E:201 ||| JJ
features  ||| S:201 E:210 ||| NNS
that  ||| S:210 E:215 ||| WDT
are  ||| S:215 E:219 ||| VBP
different  ||| S:219 E:229 ||| JJ
from  ||| S:229 E:234 ||| IN
those  ||| S:234 E:240 ||| DT
in  ||| S:240 E:243 ||| IN
the  ||| S:243 E:247 ||| DT
rest  ||| S:247 E:252 ||| NN
of  ||| S:252 E:255 ||| IN
the  ||| S:255 E:259 ||| DT
world ||| S:259 E:264 ||| NN
.  ||| S:264 E:266 ||| .
Additionally ||| S:266 E:278 ||| RB
,  ||| S:278 E:280 ||| ,
the  ||| S:280 E:284 ||| DT
region  ||| S:284 E:291 ||| NN
has  ||| S:291 E:295 ||| VBZ
a  ||| S:295 E:297 ||| DT
relatively  ||| S:297 E:308 ||| RB
young  ||| S:308 E:314 ||| JJ
population  ||| S:314 E:325 ||| NN
and  ||| S:325 E:329 ||| CC
large  ||| S:329 E:335 ||| JJ
disparities  ||| S:335 E:347 ||| NNS
in  ||| S:347 E:350 ||| IN
the  ||| S:350 E:354 ||| DT
availability  ||| S:354 E:367 ||| NN
of  ||| S:367 E:370 ||| IN
resources  ||| S:370 E:380 ||| NNS
at  ||| S:380 E:383 ||| IN
diagnostic  ||| S:383 E:394 ||| JJ
and  ||| S:394 E:398 ||| CC
treatment  ||| S:398 E:408 ||| NN
levels ||| S:408 E:414 ||| NNS
.  ||| S:414 E:416 ||| .
A  ||| S:416 E:418 ||| DT
critical  ||| S:418 E:427 ||| JJ
need  ||| S:427 E:432 ||| NN
exists  ||| S:432 E:439 ||| VBZ
for  ||| S:439 E:443 ||| IN
regional  ||| S:443 E:452 ||| JJ
guidelines  ||| S:452 E:463 ||| NNS
on  ||| S:463 E:466 ||| IN
cancer  ||| S:466 E:473 ||| NN
care ||| S:473 E:477 ||| NN
,  ||| S:477 E:479 ||| ,
including  ||| S:479 E:489 ||| VBG
those  ||| S:489 E:495 ||| DT
for  ||| S:495 E:499 ||| IN
lymphoid  ||| S:499 E:508 ||| JJ
malignancies ||| S:508 E:520 ||| NN
.  ||| S:520 E:522 ||| .
A  ||| S:522 E:524 ||| DT
panel  ||| S:524 E:530 ||| NN
of  ||| S:530 E:533 ||| IN
lymphoma  ||| S:533 E:542 ||| JJ
experts  ||| S:542 E:550 ||| NNS
from  ||| S:550 E:555 ||| IN
MENA  ||| S:555 E:560 ||| NNP
reviewed  ||| S:560 E:569 ||| VBD
the  ||| S:569 E:573 ||| DT
2009  ||| S:573 E:578 ||| CD
version  ||| S:578 E:586 ||| NN
of  ||| S:586 E:589 ||| IN
the  ||| S:589 E:593 ||| DT
NCCN  ||| S:593 E:598 ||| NNP
Clinical  ||| S:598 E:607 ||| NNP
Practice  ||| S:607 E:616 ||| NNP
Guidelines  ||| S:616 E:627 ||| NNP
in  ||| S:627 E:630 ||| IN
Oncology  ||| S:630 E:639 ||| NNP
( ||| S:639 E:640 ||| -LRB-
NCCN  ||| S:640 E:645 ||| NNP
Guidelines ||| S:645 E:655 ||| NNP
)  ||| S:655 E:657 ||| -RRB-
on  ||| S:657 E:660 ||| IN
Non-Hodgkin ||| S:660 E:671 ||| NNP
's  ||| S:671 E:674 ||| POS
Lymphoma  ||| S:674 E:683 ||| NNP
and  ||| S:683 E:687 ||| CC
Hodgkin  ||| S:687 E:695 ||| NNP
Lymphoma  ||| S:695 E:704 ||| NNP
and  ||| S:704 E:708 ||| CC
suggested  ||| S:708 E:718 ||| VBD
modifications  ||| S:718 E:732 ||| NNS
for  ||| S:732 E:736 ||| IN
the  ||| S:736 E:740 ||| DT
region  ||| S:740 E:747 ||| NN
that  ||| S:747 E:752 ||| WDT
were  ||| S:752 E:757 ||| VBD
discussed  ||| S:757 E:767 ||| VBN
with  ||| S:767 E:772 ||| IN
the  ||| S:772 E:776 ||| DT
United  ||| S:776 E:783 ||| NNP
States  ||| S:783 E:790 ||| NNPS
NCCN  ||| S:790 E:795 ||| NNP
Lymphoma  ||| S:795 E:804 ||| NNP
Panels ||| S:804 E:810 ||| NNP
.  ||| S:810 E:812 ||| .
This  ||| S:812 E:817 ||| DT
article  ||| S:817 E:825 ||| NN
presents  ||| S:825 E:834 ||| VBZ
the  ||| S:834 E:838 ||| DT
consensus  ||| S:838 E:848 ||| NN
recommendations ||| S:848 E:863 ||| NNS
.  ||| S:863 E:865 ||| .
